


18-01829-E

January 08, 2018

US Securities & Exchange Commission  
Office of FOIA and Privacy Act Operations  
100 F Street, NE Mail Stop 5100  
Washington, DC 20549-5100



Dear FOIA Office:

Under the Freedom of Information Act (FOIA), please send a copy of the following:

**A copy of: Exhibit: 10.9 to the form S-1 filed by Orexigen Therapeutics, Inc. on December 19, 2006**

In the event confidential treatment has not expired provide the specific date for which confidential treatment is still in effect. I do not need a copy of the order. We authorize up to \$61.00 in processing fees. Thank You,

**Paul D'Souza**  
Editor - Deals

**Clarivate Analytics** Friars House, 160 Blackfriars Road London, UK SE1 8EZ  
Phone: +44-2074334789  
[paul.dsouza@clarivate.com](mailto:paul.dsouza@clarivate.com)



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
STATION PLACE  
100 F STREET, NE  
WASHINGTON, DC 20549-2465

Office of FOIA Services

January 23, 2018

Mr. Paul D'Souza  
Clarivate Analytics  
160 Blackfriars Road  
London, 1U SE18EZ

RE: Freedom of Information Act (FOIA), 5 U.S.C. § 552  
Request No. 18-01829-E

Dear Mr. D'Souza:

This letter is in response to your request, dated and received in this office on January 08, 2018, for access to Exhibit 10.9, to the Form S-1, filed by Orexigen Therapeutics, Inc. on December 19, 2006.

Our search for responsive records has resulted in the retrieval of the above-requested exhibit, which consists of a one page record that may be responsive to your request. It is being provided to you with this letter.

If you have any questions, please contact me at [wadeo@sec.gov](mailto:wadeo@sec.gov) or (202) 551-8323. You may also contact me at [foiapa@sec.gov](mailto:foiapa@sec.gov) or (202) 551-7900. You also have the right to seek assistance from Ray J. McInerney as a FOIA Public Liaison or contact the Office of Government Information Services (OGIS) for dispute resolution services. OGIS can be reached at 1-877-684-6448 or [Archives.gov](http://Archives.gov) or via e-mail at [ogis@nara.gov](mailto:ogis@nara.gov).

Sincerely,

A handwritten signature in black ink that reads "Ollie R. Wade".

Ollie R. Wade  
FOIA Research Specialist

Enclosure



OREXIGEN

December 6, 2006

Jennifer Hooper McCarty, PhD  
Technology and Research Collaborations  
Oregon Health & Science University  
2525 SW 1st Avenue, Suite 120  
Mail Code: AD120  
Portland, OR 97201-4753

Re: Correction of Provisional Application Number/License Agreement with Orexigen Therapeutics, Inc. dated June 23, 2003 (the "License Agreement")

Dear Jennifer:

As we have discussed in our recent email exchanges, Section 1.01.3 of the above-referenced License Agreement contains an incorrect reference to the Therapeutic Patent that is the subject of the License Agreement. Section 1.01.3 should read in its entirety as follows:

1.01.3 **"Compositions for Affecting Weight Loss," US Provisional Patent Application No. 60/466,838 (hereinafter: **Therapeutic Patent**)**

Please indicate your agreement that the above reference is correct by signing where provided below. By executing this letter, we both agree that the License Agreement shall be amended by amending and restating Section 1.01.3 as provided above.

Thank you for your continued support of Orexigen Therapeutics.

Very truly yours,

/s/ Anthony McKinney  
Digitally signed by  
Anthony McKinney  
Date: 2006.12.06  
17:10:17 -08'00'

Anthony A. McKinney  
Chief Operating Officer

Approved and accepted the 11<sup>th</sup> day of December, 2006:

Oregon Health & Science University

By: /s/ Arundeeep S. Pradhan

Name: Arundeeep S. Pradhan  
Title: Director, Technology &  
Research Collaborations

Orexigen Therapeutics Inc.  
12481 High Bluff Drive, Suite 160, San Diego CA 92130  
Office: 858-436-8600  
Fax: 858-436-8650  
www.orexigen.com